m+Medelevator.RU
← Поиск публикаций
BMC infectious diseases · 2025

Convergence of multidrug resistance and efflux-mediated biocide tolerance in klebsiella pneumoniae ST307: implications for nosocomial infection control in Iranian hospitals.

СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Goodarzi Rezvan, Kazemi Sima, Nasershariati Mohammad Hossein, Asghari Babak

Аннотация

BACKGROUND: The relentless evolution of K. pneumoniae ST307 into a "superbug" with dual resistance to last-line antibiotics and hospital disinfectants poses an existential threat to infection control. This study characterizes the molecular epidemiology, resistance profiles, and biocide tolerance of ST307 isolates from Iranian hospitals, highlighting its role in nosocomial outbreaks.

METHODS: A multicenter cross-sectional analysis of 500 K. pneumoniae isolates (2022-2024) utilized CLSI-compliant disk diffusion, broth microdilution, and PCR for resistance genes (blaCTX-M-15, blaNDM-1,cepA, qacED1). Biocide MICs were correlated with genetic markers.

RESULTS: ST307 accounted for 30% (150/500) of isolates, predominantly from ICUs. Resistance rates included meropenem (60.0%; MIC₅₀ >32 µg/mL), ciprofloxacin (75.3%), and gentamicin (45.3%). Colistin retained efficacy (85.3% susceptibility). Elevated biocide MICs (chlorhexidine ≥ 0.5% [70.0%]; benzalkonium chloride ≥ 0.1% [65.3%]) correlated with cepA (65.3%) and qacED1 (70.0%) positivity (p < 0.01). Carbapenemase genes blaOXA-48 (22.0%) and blaNDM-1 (10.0%) co-occurred with ESBLs.

CONCLUSIONS: ST307's convergence of resistance mechanisms represents a catastrophic failure of current infection control frameworks. Without immediate interventions-such as ICU closures for deep disinfection, restricted colistin/tigecycline use, and genomic surveillance mandates-this clone will dominate Iranian hospitals within 3-5 years.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты